Insider Activity at Health Catalyst: What the Latest Moves Mean for Investors
Performance‑Based Unit Award Signals Confidence in FY 2025 Results On April 29, 2026, CEO Albert Benjamin executed a buy‑type transaction for 1,124 performance‑based restricted units (PRSUs). These units will vest only if the company meets FY 2025 performance targets, a condition that has already been satisfied, allowing the units to be converted into common shares. The award reflects the board’s confidence that Health Catalyst’s 2025 performance metrics—particularly its data‑analytics revenue growth—will be sustained into the current year. For investors, this is a bullish sign: a CEO who is rewarded only when the company meets or exceeds key metrics signals alignment between executive incentives and shareholder value.
Tax‑Withholding Sell‑to‑Cover Transaction Has No Strategic Implication Just two days later, on May 1, Benjamin sold 310 shares to cover tax withholding on vested RSUs. The sell‑to‑cover sale is routine and does not indicate a change in outlook. The price of the sale—$1.35 versus the current market price of $1.25—was the normal withholding amount. Investors should therefore view the transaction as a mechanical, not a strategic, event.
Insider Trading Pattern: A Mix of Aggressive Buying and Routine Selling Benjamin’s historical filings show a pattern of selling during periods of market volatility (e.g., February 2026) and buying large blocks when the stock dips (e.g., February 25, 2026, where he bought 930,000 shares at $0.00, likely a vesting event). His most recent sale in March 2026 (70,455 shares at $1.85) came shortly after a sharp price spike, suggesting he may be capitalizing on short‑term upside. However, his overall shareholdings have steadily increased—from 577,870 shares in September 2025 to 1,459,102 after the PRSU award—indicating a long‑term commitment to the company.
Implications for Investors and the Company’s Future Health Catalyst’s stock has been volatile, with a year‑to‑date decline of over 64% and a 52‑week low of $0.955. The CEO’s recent PRSU award and increasing stake could be interpreted as a vote of confidence that the company is on a path to recovery and sustainable growth. The upcoming first‑quarter 2026 earnings release on May 11 will be a critical test: if the company delivers on its guidance, the PRSU conversion could boost share price further, benefiting long‑term shareholders. Conversely, any missed targets could erode investor sentiment and delay the vesting of these units.
Profile of Albert Benjamin: The Executive Who Aligns with Shareholders Benjamin’s transaction history demonstrates a balanced approach: he sells when market conditions are favorable but also invests heavily when prices are low. His PRSU award—contingent on performance—shows a preference for aligning compensation with company success. The fact that he has transitioned from President/COO to CEO and retained a sizable equity position suggests a strong commitment to the firm’s strategic direction and a belief in its long‑term value proposition.
For investors, Benjamin’s insider activity—particularly the performance‑based award—offers a tangible indicator that the leadership is committed to delivering value. The next earnings announcement will be the real‑world litmus test for the company’s trajectory.
| Date | Owner | Transaction Type | Shares | Price per Share | Security |
|---|---|---|---|---|---|
| 2026-04-29 | Albert Benjamin (CEO) | Buy | 1,124.00 | 0.00 | Common Stock |
| 2026-05-01 | Albert Benjamin (CEO) | Sell | 310.00 | 1.35 | Common Stock |
